Sermorelin andIpamorelin
Perhaps the most targeted way to cause maximal growth hormone release is via thecombination of sermorelin and ipamorelin. Sermorelin is a recently developed growthhormone releasing hormone (GHRH) analogue designed to preserve the positive effectsof natural GHRH while avoiding some of the undesirable effects. Likewise, ipamorelin isthe most specific, targeted analogue of ghrelin/growth hormone secretagogue currentlyknown. When combined, these peptides act synergistically to cause extreme growth hormone release and thus maximize the benefits that GH has on muscle growth, brainhealth, heart health, and metabolism.
The targeted effects of sermorelin result in improved growth hormone effects on theheart. Research in pigs shows that sermorelin reduces cell death of cardiomyocytes,improves healing following cardiac injury, boosts the growth of collateral blood vessels.and reduces inflammation[1], [2]. A form of the ghrelin receptor has also recently beenfound in cardiac tissue where it has been shown to affect cardiac output. Administration ofghrelin and ghrelin analogues has been shown to reduce risk of abnormal heart beatsand can improve healing following cardiac injury[3].
Sermorelin and ipamorelin have specific GH-related benefits that are more potent thanwhat has been observed with other GH-releasing peptides. in addition to the heartbenefits discussed above, research has shown sermorelin to benefit the central nervous system and improve sleep quality in animal models[4], [5]. lpamorelin has been linked tobone health, insulin control in diabetes, and bowel motility (particularly following surgery)[6]-[10].
About The Author
Research by L. Edmiston, M.D. for PEPTIDE GURUS. L. Edmiston holds an M.D. fromCase Western Reserve University School of Medicine and a B.S. in molecular biology.
Scientific JournalAuthor
Richard F. Walker, Ph.D, R.Ph, lead author of A better approach to management of adult-onset growth hormone insufficiency?”, received a BS in pharmacy from RutgersUniversity, a MS in Biochemistry from New Mexico State University and a PhD in aphysiology from Rutgers University. He holds postdoctoral fellowships inneuroendocrinology and neuropharmacology at Duke University College of Medicine(Center for the Study of Aging and Human Development) and the University of California.Berkeley,respectively.
Richard F. Walker, Ph.D, R.Ph is being referenced as one of the leading scientistsinvolved in the research and development of Sermorelin. In no way is this doctor/scientistendorsing or advocating the purchase, sale, or use of this product for any reason. Thereis no affiliation or relationship, implied or otherwise, between PEPTIDE GURUS and thisdoctor. The purpose of citing the doctor is to acknowledge, recognize, and credit theexhaustive research and development efforts conducted by the scientists studying thispeptide. Richard F. Walker, Ph.D, R.Ph is listed in [11] under the referenced citations.
Resources
1.L.L. Bagno et al., “Growth Hormone-Releasing Hormone Agonists ReduceMyocardial Infarct Scar in Swine With Subacute lschemic Cardiomyopathy,” J. AmHeart Assoc.Cardiovasc.Cerebrovasc. Dis., vol. 4, no.4, Mar. 2015.[PubMed]
2.R. M. Kanashiro-Takeuchi et al., “New therapeutic approach to heart failure due tomyocardial infarction based on targeting growth hormone-releasing hormonereceptor,”Oncotarget, vol.6, no.12,pp.9728-9739, Mar. 2015.[PubMed]
3.T. Tokudome, K. Otani, M. Miyazato, and K. Kangawa, “Ghrelin and the heart,Peptides, vol.111,pp.42-46,2019.[PubMed]
4.S. Tang et al., “Interactions between GHRH and GABAARs in the brains of patientswith epilepsy and in animal models of epilepsy,” Sci. Rep., vol.7, Dec. 2017.[PubMed]
5.B.S. Shepherd et al., “Endocrine and orexigenic actions of growth hormonesecretagogues in rainbow trout (Oncorhynchus mykiss),” Comp. Biochem. PhysiolA.Mol.Integr. Physiol., vol. 146, no.3, pp.390-399, Mar. 2007.[PubMed]
6.N. B. Andersen, K. Malmlöf, P. B. Johansen, T. T. Andreassen, G. ②rtoft, and H.Oxlund, “The growth hormone secretagogue ipamorelin counteracts glucocorticoid.induced decrease in bone formation of adult rats,” Growth Horm. IGF Res. Off. J.Growth Horm.Res.Soc.Int.IGF Res.Soc., vol.11,no.5,pp.266-272,0ct. 2001[PubMed]
7.J.Svensson et al., “The GH secretagogues ipamorelin and GH-releasing peptide-6increase bone mineral content in adult female rats,” J. Endocrinol.. vol. 165. no. 3.pp.569-577,Jun.2000.[PubMed]
8.N. K. Aagaard et al., “Growth hormone and growth hormone secretagogue effectson nitrogen balance and urea synthesis in steroid treated rats,” Growth Horm. lGFRes.Off. J.Growth Horm.Res.Soc.Int.lGF Res.Soc., vol. 19, no.5, pp.426-431,Oct.2009.[PubMed]
9.E.Adeghate and A.S. Ponery, “Mechanism of ipamorelin-evoked insulin releasefrom the pancreas of normal and diabetic rats,” Neuro Endocrinol. Lett.. vol. 25, no.6, pp.403-406, Dec.2004.[PubMed]
10.D.E.Beck,W.B.Sweeney, M.D. McCarter, and lpamorelin 201 Study Group*Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimeticipamorelin for the management of postoperative ileus in bowel resection patients,Int.J. Colorectal Dis., vol.29,no.12,pp.1527-1534, Dec.2014.[PubMed]
11.R.F. Walker, “Sermorelin: A better approach to management of adult-onset growthhormone insufficiency?,”Clin.Interv.Aging, vol. 1, no.4, pp.307-308, Dec.2006[PubMed]
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE AREFOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. in-vitro studies(Latin: in glass) are performed outside of the body. These products are not medicines ordrugs and have not been approved by the FDA to prevent, treat or cure any medicalcondition, ailment or disease. Bodily introduction of any kind into humans or animals isstrictly forbidden by law.
